---
figid: PMC7313774__ofaa219f0001
figlink: pmc/articles/PMC7313774/figure/F1/
number: F1
caption: Figure compares healthy alveolus (left) to injured alveolus (right) from
  severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced proinflammatory
  host response and proposed targets of immunomodulatory therapy in coronavirus disease
  2019 (COVID-19)-related acute lung injury/acute respiratory distress syndrome. Vascular
  endothelial growth factor inhibitor (VEGF) inhibitors (green text box) bind to and
  neutralize VEGF to inhibit pulmonary edema caused by VEGF overexpression. Interleukin-6
  receptor (IL-6R) inhibitors (purple text box) inhibit both membrane-bound IL-6R
  and soluble IL-6R leading to inhibition of IL-6R activation and hyper-IL-6 formation,
  whereas siltuximab also binds directly to IL-6. Janus kinase (JAK) inhibitors (red
  text box) inhibit the activity JAK enzymes thereby interfering with the JAK/signal
  transducer and activator of transcription pathway responsible for inflammatory cytokine
  signaling. CD24Fc (pink text box) interacts with danger-associated molecular patterns
  (DAMPs) and sialic acid-binding Ig-like lectins (Siglecs) to inhibit nuclear factor-kappa
  B activation and release of inflammatory cytokines. Anti-CD147 antibodies (yellow
  text box) inhibit CD147, which may lead to decreased SARS-CoV-2 replication. Tumor
  necrosis factor (TNF)-α inhibitors (black text box) bind to TNF-α to prevent binding
  to TNF-α receptor (TNFR) sites and subsequent release of inflammatory cytokines.
  Interleukin-1R antagonists (blue text box) block activity of IL-1β by competitively
  inhibiting binding to IL-1R. RBC, red blood cell; TLR, Toll-like receptor. Created
  with BioRender.com.
pmcid: PMC7313774
papertitle: 'Countermeasures to Coronavirus Disease 2019: Are Immunomodulators Rational
  Treatment Options—A Critical Review of the Evidence.'
reftext: Daniel B Chastain, et al. Open Forum Infect Dis. 2020 Jul;7(7):ofaa219.
pmc_ranked_result_index: '42749'
pathway_score: 0.7898674
filename: ofaa219f0001.jpg
figtitle: 'Countermeasures to Coronavirus Disease 2019: Are Immunomodulators Rational
  Treatment Options—A Critical Review of the Evidence'
year: '2020'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7313774__ofaa219f0001.html
  '@type': Dataset
  description: Figure compares healthy alveolus (left) to injured alveolus (right)
    from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced proinflammatory
    host response and proposed targets of immunomodulatory therapy in coronavirus
    disease 2019 (COVID-19)-related acute lung injury/acute respiratory distress syndrome.
    Vascular endothelial growth factor inhibitor (VEGF) inhibitors (green text box)
    bind to and neutralize VEGF to inhibit pulmonary edema caused by VEGF overexpression.
    Interleukin-6 receptor (IL-6R) inhibitors (purple text box) inhibit both membrane-bound
    IL-6R and soluble IL-6R leading to inhibition of IL-6R activation and hyper-IL-6
    formation, whereas siltuximab also binds directly to IL-6. Janus kinase (JAK)
    inhibitors (red text box) inhibit the activity JAK enzymes thereby interfering
    with the JAK/signal transducer and activator of transcription pathway responsible
    for inflammatory cytokine signaling. CD24Fc (pink text box) interacts with danger-associated
    molecular patterns (DAMPs) and sialic acid-binding Ig-like lectins (Siglecs) to
    inhibit nuclear factor-kappa B activation and release of inflammatory cytokines.
    Anti-CD147 antibodies (yellow text box) inhibit CD147, which may lead to decreased
    SARS-CoV-2 replication. Tumor necrosis factor (TNF)-α inhibitors (black text box)
    bind to TNF-α to prevent binding to TNF-α receptor (TNFR) sites and subsequent
    release of inflammatory cytokines. Interleukin-1R antagonists (blue text box)
    block activity of IL-1β by competitively inhibiting binding to IL-1R. RBC, red
    blood cell; TLR, Toll-like receptor. Created with BioRender.com.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - VEGFD
  - VEGFB
  - PGF
  - VEGFA
  - VEGFC
  - FLT1
  - FLT4
  - KDR
  - IL6R
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - GAK
  - STAT1
  - STAT5A
  - STAT6
  - STAT2
  - STAT3
  - STAT4
  - STAT5B
  - BSG
  - TNF
  - IL1B
  - IL1R1
  - RASA1
  - erlotinib
  - ruxolitinib
  - fedratinib
  - Gap
  - edematous
  - SARS-CoV-2
genes:
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT1
  entrez: '2321'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: IL-6R
  symbol: IL6R
  source: hgnc_symbol
  hgnc_symbol: IL6R
  entrez: '3570'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: IL-6R
  symbol: IL6R
  source: hgnc_symbol
  hgnc_symbol: IL6R
  entrez: '3570'
- word: IL-6R
  symbol: IL6R
  source: hgnc_symbol
  hgnc_symbol: IL6R
  entrez: '3570'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK1
  entrez: '3716'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK2
  entrez: '3717'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK3
  entrez: '3718'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: TYK2
  entrez: '7297'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK1
  entrez: '3716'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK2
  entrez: '3717'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: JAK3
  entrez: '3718'
- word: JAK
  symbol: JAK
  source: bioentities_symbol
  hgnc_symbol: TYK2
  entrez: '7297'
- word: GAK
  symbol: GAK
  source: hgnc_symbol
  hgnc_symbol: GAK
  entrez: '2580'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT1
  entrez: '6772'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT5A
  entrez: '6776'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT6
  entrez: '6778'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT2
  entrez: '6773'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT3
  entrez: '6774'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT4
  entrez: '6775'
- word: STAT
  symbol: STAT
  source: bioentities_symbol
  hgnc_symbol: STAT5B
  entrez: '6777'
- word: CD147
  symbol: CD147
  source: hgnc_alias_symbol
  hgnc_symbol: BSG
  entrez: '682'
- word: TNF-a
  symbol: TNFA
  source: hgnc_prev_symbol
  hgnc_symbol: TNF
  entrez: '7124'
- word: IL-1B
  symbol: IL-1B
  source: hgnc_alias_symbol
  hgnc_symbol: IL1B
  entrez: '3553'
- word: TNF-a
  symbol: TNFA
  source: hgnc_prev_symbol
  hgnc_symbol: TNF
  entrez: '7124'
- word: IL-1R
  symbol: IL1R
  source: hgnc_prev_symbol
  hgnc_symbol: IL1R1
  entrez: '3554'
- word: IL-1R
  symbol: IL1R
  source: hgnc_prev_symbol
  hgnc_symbol: IL1R1
  entrez: '3554'
- word: Gap
  symbol: GAP
  source: hgnc_alias_symbol
  hgnc_symbol: RASA1
  entrez: '5921'
chemicals:
- word: erlotinib
  source: MESH
  identifier: C400278
- word: ruxolitinib
  source: MESH
  identifier: C540383
- word: fedratinib
  source: MESH
  identifier: C528327
- word: Gap
  source: MESH
  identifier: C514423
diseases:
- word: edematous
  source: MESH
  identifier: D004487
- word: SARS-CoV-2
  source: MESH
  identifier: C000657245
figid_alias: PMC7313774__F1
redirect_from: /figures/PMC7313774__F1
figtype: Figure
---
